Biohaven Pharma (BHVN) Misses Q3 EPS by 10c

Biohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($1.44), $0.10 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $0.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand